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Abstract
Tobacco products, both combustible and smokeless, contain abundant
amounts of toxic chemicals and carcinogens capable of causing extensive damage to the
body. Tobacco specific nitrosamines, including 4-(methylnitrosoamino)-1-(3-pyridyl)-1butanone (NNK) and N’-nitrosonornicotine (NNN), are among the most potent of these
carcinogens and are capable of eliciting cellular transformations within the body after
bioactivation by cytochrome P450 enzymes. In order to reduce the harm associated with
smokeless tobacco, a recombinant anti-NNK antibody has been constructed from a
hybridoma secreting a mouse monoclonal antibody specific for NNK.
In work performed previously, hybridomas were created by constructing a
structurally-related benzoyl derivative to facilitate coupling to NNK-carrier proteins,
which were then used to immunize BALB/C mice. Splenocytes from mice bearing NNKspecific antibodies were used for hybridoma production and the final product was
isolated, characterized and found to secrete a high-affinity anti-NNK monoclonal
antibody. In the current study, the heavy and light chain antibody F(ab) fragments were
cloned, sequenced and inserted in tandem into an expression vector with an FMDV Furin
2A cleavage site between them. Expression in HEK 293 cells revealed a functional F(ab)
with similar binding features to that of the parent hybridoma. This study lays the
groundwork for synthesizing transgenic tobacco that expresses carcinogen-sequestration
properties, thereby rendering it less harmful to consumers.
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Introduction

1.1.1 Negative Health Effects of Chronic Tobacco Use
Tobacco use continues to be the main cause of lung cancer and cardiovascular
disease worldwide and has been estimated to kill more than 6 million people each year
[1,2]. Despite decades of continuous efforts to control the production and marketing of
tobacco products, especially to youths, countless people still engage in this dangerous
habit [3]. On average, it has been shown that cigarette smoking can reduce the lifespan
of an individual by 13.5 years [4]. According to the World Health Organization,
approximately one person dies every six seconds due to tobacco use, which accounts for
one in ten adult deaths. The American Heart Association estimates that in 2004, tobacco
use cost the United States $193 billion dollars in healthcare and lost productivity.
Over the past decade, the number of people who smoke in the United States has
declined by a small percentage. In 2011, the CDC estimated that there was about a 2-3%
drop in the number of male and female smokers over a span of nine years (2000-2009).
However, worldwide it has been estimated that there are 6 billion people who currently
use some form of tobacco and out of this population, 80% live in low- and middleincome families [5]. These numbers are concerning considering that over 6,000 harmful
chemicals and toxicants are consumed by an individual when a single cigarette is
smoked. Around sixty of these compounds have been classified as known or suspected
carcinogens and include polycyclic aromatic hydrocarbons, formaldehyde, benzene and
tobacco specific nitrosamines (TSNAs) [6,7].
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1.1.2 Tobacco Specific Nitrosamines
The most abundant and potent carcinogens found within cigarettes and smokeless
tobacco products are tobacco specific nitrosamines, 4-(methylnitrosoamino)-1-(3pyridyl)-1-butanone (NNK), 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
and N’-nitrosonornicotine (NNN) [8,9]. Each of these nitrosamines contains a single N’
nitroso moiety that is responsible for the carcinogenic nature of the compounds. NNK
and NNN are classified as Group 1 human carcinogens by the International Agency for
the Research on Cancer (IARC) and are formed from the nitrosation of the tobacco
alkaloid nicotine [10]. This process involves the interaction of nicotine with a nitrate,
nitrite or nitrogenous gas and occurs both during the curing and processing of tobacco
and in the mammalian organism itself [11]. N’-nitrosonornicotine (NNN) is additionally
formed by the demethylation of nicotine into nornicotine, which is then followed by
nitrosation of the pyrrolidine nitrogen of nornicotine.
Minor secondary tobacco alkaloids such as anatabine and anabasine also
participate in the formation of tobacco specific nitrosamines, but to a lesser extent than
nicotine (Figure 1.1). Through reductive metabolism of NNK, NNAL is formed, which
is another potent carcinogen [6]. It can be detected in the plasma and urine of cigarette
users as well as people exposed to secondary smoke, making it an effective biomarker for
the uptake of NNK. Higher urine NNAL has been proven to coincide with poorer
physical health, restricted activity and dyspnea, which is an early predictor of lung cancer
susceptibility [12,13].
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Figure 1.1 Nitrosation of Tobacco Alkaloids [14]
Nitrosation of tertiary and secondary minor tobacco alkaloids results in the formation of
Tobacco Specific Nitrosamines, some of the most potent chemicals contained within
tobacco products.

1.1.3 Metabolic Activation of TSNAs
In order to elicit cellular transformations within the body, the nitrosamines must
be metabolically activated by cytochrome P450 enzymes such as CYP2A6 and
CYP2A13, integral membrane proteins located within the endoplasmic reticulum of cells
[15]. Although both enzymes play an important role in activation, CYP2A13 has been
shown to activate NNK with a 61- to 214- fold greater catalytic efficiency than CYP2A6
[16-18]. Via hydroxylation pathways, NNK and NNN are metabolized into either
methylating (7-methylguanine, O6-methylguanine) or pyridyloxobutylating (7-POB
guanine, O2-POB thymine, O6-POB guanine) agents capable of forming DNA adducts,
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which initiate mutations that contribute to tumor formation [8,6, 10, 19]. (Figure 1.2) In
the current study, NNK is focused on exclusively due to the fact that it is the most potent
carcinogen identified in smokeless and combustible tobacco products [20].

Figure 1.2 Metabolic Activation of NNK and DNA Adduct Formation [21]
Metabolic activation of NNK by Cytochrome P450 enzymes results in reactive
intermediates that alkylate DNA. This leads to the formation of Pyridyloxobutyl or
Methyl DNA adducts that are responsible for the initiation of tumor development.

In rodent studies, NNK has been shown to induce tumors in the lung, nasal and
oral cavities, esophagus, liver and exocrine pancreas irrespective of the route of
administration [8]. Further evidence for the carcinogenicity of NNK has been established
in several in vitro studies whereby the nitrosamine induces the proliferation of normal
10

human lung epithelial cells, small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC) [15, 22,23, 24]. Proliferation can occur via alternative epigenetic mechanisms
whereby the nitrosamine ligates with nicotinic acetylcholine receptors (nAChRs) located
on the surface of epithelial cell membranes. These receptors are integral membrane
proteins formed by the assembly of five trans-membrane subunits (α3, α5, α7, β4) and
exist in either homomeric or heteromeric forms [1]. (Figure 1.3) NNK binding causes a
conformational change in the receptor, which induces a channel within the membrane to
open, allowing for the influx of Na+ and Ca+2 ions. Simultaneously, the efflux of K+ ions
occurs, resulting in membrane depolarization and the opening of voltage-gated Ca+2
channels. This influx of Ca+2 leads to enhanced activity in signaling pathways such as
Protein Kinase C and A, Ras and PI3K, resulting in cell proliferation, angiogenesis, and
apoptotic inhibition [25,26]. Figure 1.4

Figure 1.3- Nicotinic Acetylcholine Receptors [27]
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Figure 1.4- Signaling Pathways Activated by NNK
[http://dx.doi.org/10.1016/j.jecm.2011.10.003]

1.1.4 Neurobiological Effects of Nicotine
Considering all the facts and statistics pertaining to the detrimental effects of
tobacco use, many individuals still succumb to this habit, and either refuse or are unable
to quit. Out of the number of people that make the attempt, less than 5% are actually
successful and only about one fifth of these individuals remain abstinent in the long run
[28,1]. One of the reasons for this is that nicotine, the main component of tobacco, is
extremely addictive. Once nicotine is inhaled, it rapidly passes through the blood brain
barrier and binds to nicotinic acetylcholine receptors, leading to the activation of the
“reward” circuitry of the brain and subsequent release of chemicals such as dopamine,
glutamate and GABA. These chemicals elicit feelings of relaxation and euphoria. Long-
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term usage of nicotine eventually results in neurobiological changes that lead to tolerance
and addiction [29,30]. The effects of nicotine are so powerful and consuming that the
overall experience is often compared to the effects elicited during use of hardcore drugs
of abuse, i.e. cocaine and heroin [28].

1.1.5 Tobacco Harm Reduction
In the past few years, some public health officials have turned to tobacco harm
reduction as an alternative means to reduce an individual’s exposure to adverse chemicals
and toxins within tobacco products. According to the American Council on Science and
Health, tobacco harm reduction can be defined as “the substitution of far safer sources of
nicotine by those smokers who are unable or unwilling to achieve nicotine/tobacco
abstinence”. In countries such as Sweden, the use of snus, a moist powdered tobacco that
is a variant of dry snuff, contains significantly lower levels of nitrosamines and has
resulted in a marked decrease in cigarette smoking and the number of tobacco-related
deaths among both men and women [31]. An epidemiological study done by Gartner in
2007 claimed that the health benefits from switching to low nitrosamine smokeless
tobacco products are nearly as large as those from quitting tobacco use altogether [32].
In 2011, Rodu provided evidence, based on a comprehensive review of existing scientific
and medical literature, that smokeless tobacco products on average have significantly less
toxins and the risk of developing lung cancer is essentially abolished, making their use
90% safer than that of cigarettes [33]. In 2002, the Royal College of Physicians of
London stated that the consumption of smokeless tobacco is 10-1,000 times less
hazardous than smoking [33]. PREPs (non-combustible potential reduced exposure
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products), have also been developed to reduce harmful tobacco exposure and include
compressed tobacco tablets, nicotine water and patches, medicinal nicotine products and
low nitrosamine cigarettes and smokeless tobacco products [34,35]. Although these
products have been shown to be effective, many long-term tobacco users fail to quit
because of the overpowering addictive properties of nicotine. Reduced exposure
products that do not interfere with the free passage of nicotine within the brain would
potentially save millions of lives worldwide.

1.1.6 Monoclonal Antibodies
In order to investigate alternative means for tobacco harm reduction, certain
immunotherapies focused on mitigating the effects of debilitating drugs of abuse are
currently in development. One such therapy involves the passive administration of polyor monoclonal antibodies specific for drugs such as nicotine, heroin, cocaine and
methamphetamine [36]. These antibodies are particularly effective due in part to their
small molecular size, allowing for extensive tissue distribution and long elimination halflife following administration [37]. In 2009, Roiko et al passively immunized mice with a
monoclonal antibody against nicotine and was able to successfully reduce the levels of
the chemical within the brain [38]. Another study conducted by Norman et al in 2007
demonstrated that the intravenous administration of an anti-cocaine monoclonal antibody
prior to the injection of cocaine was able to significantly decrease the levels of the
substance within the brain of mice [39]. These are just a few of the many studies that
highlight the potential for antibody-mediated interception as a therapeutic means to
ameliorate or eliminate the toxicity associated with certain chemicals.
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1.1.7 Recombinant Antibodies
The production of recombinant antibodies that express high affinity binding sites
have become particularly attractive for immune-mediated sequestration of harmful toxins
and chemicals. A way in which these sites can be created is through the use of 2A
peptides derived from certain single-stranded RNA viruses. These peptides, which are
usually around 18 amino acids long, mediate autonomous intra-ribosomal self-processing
of multiple proteins from a single open reading frame [40]. In the current study, a 2A
peptide derived from Foot and Mouth Disease Virus (FMDV) was used specifically for
this purpose. The peptide originates from the viral family Picornaviridae, and functions
by initiating “ribosomal skipping” at the glycin-proline peptide bond located within its
highly conserved functional motif (D (V/I) EXNPGP) [41]. (Figure 1.5) This results in
interruption of peptide bond formation at this location, leading to cleavage of the
upstream protein. After this cleavage event occurs, translation of the downstream protein
resumes (Figure 1.6). All that remains of the 2A sequence on this protein in the proline.
In order to remove the remainder of the 2A sequence from the upstream protein, a furin
cleavage site is usually inserted just upstream of the sequence. Upon cellular processing,
the remainder of the sequence is removed at this site and what remains are equal
concentrations of both the downstream and upstream proteins.
In the work described herein, the 2A peptide derived from FMDV was used to create
an anti-NNK recombinant binding site. This approach enabled the parent hybridoma to be
expressed as a single chain antibody fragment. This antibody format is beneficial because
its smaller structure facilitates ease of cloning into expression vectors, elicits minimal
immunogenicity and is rapidly cleared from the circulation [31]. Following production,
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the recombinant antibody, delivered by the appropriate vector or admixed with the
product, may be used to passively protect the oral cavity prior to or during smokeless
tobacco use. NNK bioactivation will be prevented once the high-affinity antibody binds
to its target and the complex is predicted to be harmlessly eliminated through
expectoration. According to a study conducted by Hecht et al (2007), daily exposure of
NNK in smokeless tobacco users is ~6 µg, when an average of 2 grams tobacco is
chewed. The study also found that the average concentration of NNK in expectorated
saliva of 15 smokeless tobacco users was 3.2 nmol [42]. Based on these findings, tests
will need to be conducted to determine the optimal molar concentration of binding
fragment vs. NNK in saliva in order to elicit the desired protective response. After the
appropriate concentrations have been determined, the safety and efficacy of this approach
will be tested in animal models and humans.
Another consideration that must be taken into account is the complex environment in
which the recombinant binding fragment will be introduced. The oral cavity contains
many different cells responsible for maintaining homeostasis and initiating proteolytic
degradation of food and foreign substances, some of which include lymphocytes, acinar
cells, squamous epithelial cells and bacterial cells. In addition to this, saliva also contains
many different electrolytes, anti-bacterial compounds and several proteases [43]. Tests
will be necessary to determine the extent to which these components may affect antigenantibody complex formation within the oral cavity.
A long-term goal of the current proposal is to produce transgenic tobacco that allows
the free passage of nicotine from the product, but blocks the bioavailability of
carcinogens like NNK by immuno-interception. The expression of recombinant
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antibodies in tobacco has already proven to be technically feasible and will allow for the
large-scale production of therapeutic antibodies at relatively low costs, making this
approach particularly attractive to individuals seeking cost-effective tobacco harm
reduction products.

Figure 1.5: Highly Conserved 2A Sequences [44]
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Figure 1.6: Mechanism of Cleavage Event Initiated by Viral 2A Peptide
Ribosomal skipping is initiated by the viral 2A peptide through interruption of the
peptide bond between the glycine and proline that are located within its highly conserved
functional motif.

http://www.google.com/imgres?imgurl=http://education.expasy.org/images/Ribskip.jpg&imgrefurl=http://v
iralzone.expasy.org/all_by_protein/914.html
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Materials and Methods
2.1.1 Cloning and Characterization of F(ab)-generating single chain antibody:
Four T-75 culture flasks containing 7F cells in Hybricare Media supplemented with
MEM Sodium Pyruvate (100 mM), MEM Non-essential AA (10 mM), L-Glutamine (200
mM), 1× AB/AM and 20% heat inactivated FBS were sent to Creative Biolabs (Shirley,
NY, USA) for amplification and sequencing. An intervening 2A motif derived from
FMDV was cloned into the expression vector 7Fmab_pFab-HL via restriction enzymes
EcoRI and NotI. The amplified VH and VL Immunoglobulin chains of the antibody
flanked the peptide linker and a furin cleavage site was inserted just upstream of the 2A
motif. The construct was transfected into HEK293 cells to allow for cleavage and
subsequent expression of the recombinant binding fragment.

Under denaturing

conditions, an SDS-PAGE was performed according to [45] in order to verify cleavage
and the appropriate molecular weight of the polyprotein. Next, a Western Blot was
performed to test the protein’s immunoreactivity to a Fab-specific antibody. The primary
antibody used was an Anti-Mouse IgG (Fab-specific) conjugated to alkaline phosphatase
(Sigma-Aldrich, St. Louis, MO, USA) and diluted 1:10,000 in PTA/BSA 0.1% buffer
(0.05 M phosphate buffer saline (PBS) + tween 20 (Aldrich, Milwaukee, WI, USA) +
0.01% sodium azide (Fluka, Buchs Sg, Switzerland)), with 0.1% ovalbumin added to the
buffer pH 7.4. A second Western Blot was performed using a 1:40,000 dilution of the
Anti-Mouse IgG (Fab-specific) antibody in order to better visualize the Immunoglobulin
chains.
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2.1.2 ELISA of F(ab):
ELISA was performed to test the binding of the F(ab) to its target antigen (NNK). One
96-well plate was coated with 10 µg/mL NNKB-Ovalbumin and 10 µg/mL Ovalbumin.
Each of the coating solutions were diluted in 0.05 M sodium carbonate buffer (SigmaAldrich Inc. St. Lous, MO, USA), pH 9.6. The plate was wrapped in two layers of
Parafilm and incubated at room temperature (21 °C) overnight. The next morning, a 1:8
dilution of the protein was made in PTA/BSA 0.1% buffer. A 1:2500 dilution of 7F was
also made up to test on the same plate in order to compare the binding efficacies of the
complete IgG versus the anti-NNK binding fragment. After the solutions were mixed, the
96-well plate was washed five times with PTA/BSA 0.1% buffer using a Bio-Tek
ELx405 Microplate Washer. The plate was then blotted dry on paper towels. Fifty
microliters/well of each antibody was added to their corresponding locations within the
plate. The plate was then placed at room temperature for overnight incubation. The
following morning, the plate was washed three times in PTA/BSA 0.1% buffer and
blotted dry as above. A 1:1,000 dilution of Polyvalent Anti-Mouse IgG, A, M antibody
conjugated to Alkaline Phosphatase was made up for application to the wells containing
the 7F antibody. A 1:10,000 dilution of anti-Mouse IgG (Fab-specific) antibody
conjugated to Alkaline Phosphatase was made for application to the wells containing the
F(ab). Fifty microliters of each solution was then added to the appropriate wells. After a
two hour incubation at room temperature the plate was washed 3 times once again using
PTA/BSA 0.1% buffer. Two 5 mg tablets of the phosphatase substrate PNPP (SigmaAldrich, Lot # 120N8201V, St. Louis, MO, USA) were diluted in 10 mL of 0.05 M
sodium carbonate + 0.001 M magnesium chloride (Sigma-Aldrich Inc. St. Louis MO,
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USA) pH 9.8 and 50µL of this mixture was added to each of the wells. Results were then
read at 25, 50, and 100 min using a Bio-Tek uQuant Universal Microplate
Spectrophotometer set at a wavelength of 405 nm (Biotek Instruments, Winooski, VT,
USA).

2.1.3 Competitive ELISA of F(ab):
A competition ELISA using the F(ab) was performed with NNK as the soluble
competitor. The monoclonal antibody 7F was used as a positive control. A stock solution
of NNK was made at a concentration of 48.25 mM (10 mg/mL) in de-ionized water. This
solution was then diluted to 966 µM, 292 µM, 88.0 µM and 26.0 µM. 125 µL of each
dilution of NNK was added to separate test tubes, which contained 125uL of either a 1:4
dilution of F(ab) or a 1:1250 dilution of 7F. The samples were then mixed and incubated
at room temperature for 30 min in order to allow for appropriate competition to occur. 50
µL of each test tube containing the samples were added to their corresponding wells.
After a 2 hr incubation period, plates were washed three times as above. A 1:10,000
dilution of anti-Mouse IgG (Fab-specific) antibody conjugated to Alkaline Phosphatase was
then applied to the F(ab)-containing wells and a 1:1,000 dilution of Anti-Mouse IgG, A, M
antibody conjugated to Alkaline Phosphatase was applied to 7F-containing wells, each at
a volume of 50 µL/well. Plates were then washed as above followed by PNPP substrate
addition. Results were read at 25, 50 and 100 min intervals with the Bio-tek
spectrophotometer set at a wavelength of 405 nm.
.

21

2.1.4 Cell Viability Assay:
To test the ability of the F(ab) to block the harmful effects of NNK on susceptible
cells, the lung adenocarcinoma cell line A549 was purchased from ATCC. Cells were
grown in F-12K media supplemented with 10 % FBS and 1x Ab/Am. Media was
changed every 2-3 days and cells were passaged when they reached 70-80% confluency.
To determine cell viability after exposure to NNK, cells were transferred to an opaque
96-well plate at a density of 6 x 10³ cells per well. After 24 hours in F-12K media
supplemented with 10% FBS, media was switched to 0.05% FBS to remove any
exogenous growth factors that would affect the interaction of NNK with the cells. A 10
mg/mL stock solution of NNK was diluted to 2,500 µg/mL, 250 µg/mL, 25 µg/mL, 2.5
µg/mL and 0.25 µg/mL in F-12K media containing 0.05% FBS. After another 24 hours,
the NNK solutions were added at 100 µL/well to the plate. Cell viability of the cells was
determined 24 hours later by performing a Cell Titer Glo Assay. Results were read on a
FluoStar Optima Luminometer from BMG Labtech (Cary, NC, USA) at 45 minutes post
application of the Cell Titer Glo reagent per manufacturer’s protocol.

2.1.5 BrdU Proliferation Assay:
A BrdU Proliferation Assay was performed in order to determine the effect of
NNK on transformed lung epithelial cells in vitro. NCI-H441 cells were purchased from
ATCC and grown in RPMI-1640 media supplemented with 10% FBS and 1x Ab/Am.
Media was changed every 4-5 days and cells were passaged when they reached 70-80%
confluency. To determine cell proliferation after exposure to varying concentrations of
NNK, freshly trypsinized cells dilute either 1:10 or 1:15 in fresh RPMI-1640 media
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supplemented with 10% FBS and 1x Ab/Am, were seeded in 96-well plates at a density
of 5 x 103/well. Plates were then covered and placed in 37°C, 5% CO2 for 24 hrs. The
following day, cells were serum-starved to remove any exogenous growth factors by
replacing media with 0.12% FBS. Cells were then placed in 37°C, 5% CO2 for an
additional 24 hrs. After cells reached 30% confluency, 10-fold serial dilutions of NNK
(10mg/mL) mixed with RPMI-1640 media supplemented with 0.12% FBS were added to
corresponding wells (0.483 µM, 4.83 µM, 48.3 µM, 483 µM, and 4,830 µM NNK).
Control wells contained cells mixed with RPMI-1640 media supplemented with 0.12%
FBS and no NNK. Plates were placed in 37°C, 5% CO2 for a 2 hour incubation period.
20 µL/well of BrdU reagent was then added to the appropriate wells and cells
were incubated for a total of 24hrs. Cells were then fixed and denatured according to the
manufacturer’s protocol. Wash buffer was added to the plates for a total of three times,
aspirated after the final wash and blotted dry on paper towels. 100 µL/well of anti-BrdU
monoclonal antibody was then added to the appropriate wells and incubated at room
temperature for 1 hour. Plates were washed as above and blotted dry on paper towels.
Goat anti-Mouse IgG, Peroxidase Conjugate was added at 100 µL/well and incubated at
room temperature for a total of 30 min. Plates were once again washed 3 times and
blotted dry on paper towels. 100 µL/well of TMB Peroxidase Substrate were added to
corresponding wells and incubated at room temperature in the dark for 30 min. After the
30 min. incubation period, 100 µL/well of the acid Stop Solution was pipetted into the
appropriate wells. Positive wells which corresponded to proliferating cells changed from
blue to bright yellow. Results were read using a Bio-Tek uQuant Universal Microplate
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Spectrophotometer set at a wavelength of 490 nm (Biotek Instruments, Winooski, VT,
USA).

2.1.6 Reconstruction of Plasmid Encoding Anti-NNK Recombinant Binding
Fragment
Using the previously cloned antibody sequence, adjustments were made to the
first plasmid vector (7F Fab) to improve overall binding affinity of the anti-NNK
recombinant binding fragment. 7F VL-CL DNA was amplified from the 7F Fab vector
using the primers U7fvl/Dck and ligated into pUC57 via PstI/MfeI, yielding the vector
designated as pUC57s-7FVLCL. 7F VH-CH1 DNA was then amplified from the 7F Fab
vector using the primers U7fvh/Dch1 and ligated into pUC57-7FVLCL via SacII/AvrII.
The identity of the sequences was verified by DNA sequencing. The final vector was
designated as pUC57s-7FHL. The plasmid was amplified via bacterial transformation in
E.Coli Top10 competent cells.

2.1.7 Validation of Plasmid Vector Sequence
Before transcription/translation of the plasmid was performed, the DNA was resequenced to confirm proper identity. E-Coli Top10 competent cells containing the
plasmid vector, sent initially from Creative Biolabs, were streaked onto LB agar plates
containing ampicillin and grown overnight at 37°C. Single colonies were inoculated in 35 mL LB broth containing ampicillin and incubated for 16-18 hrs in a 37° C shaking
incubator. The following day, plasmid was purified using a Qiagen Plasmid Mini Prep.
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The appropriate primers were purchased and the DNA was amplified using PureTaq
ready to go PCR beads from Fisher Scientific.
Restriction Digests were then performed to verify proper molecular weight of the
vector. 5 µL NeBuffer EcoRI + 0.5 µL BSA + 33.5 µL ddH20 + 10 µL DNA template
(22.3 ng/ µL) + 1 µL EcoRI were added to a 1.5 mL vial to linearize the plasmid. 1 µL
EcoRI and 1 µL Not I were then added to 5 µL NeBuffer EcoRI + 0.5 µL BSA + 32.5 µL
ddH20 + 10 µL DNA template (22.3 ng/ µL) in order to confirm proper molecular weight
of the insert. 5µL NeBuffer EcoRI + 0.5 µL BSA, 32.5 µL ddH20 + 10 µL PCR product
+ 1 µL each of enzymes Eco RI and Not I were then added to a 1.5 mL vial. Each of the
three samples were then mixed gently and placed at 37°C for 2 hours. Agarose gel
analysis was performed and amplified DNA fragments resembling the insert were cut out
from the gel and purified using a Qiaquick Gel Extraction Kit from Qiagen. Final
product was sent out for sequencing.

2.1.8 Coupled Transcription/Translation of Purified Plasmid
For expression of the anti-NNK recombinant binding fragment, a TNT T7 Quick
Coupled Transcription/Translation System from Promega was used. DNA was purified
and then concentrated using a DNA Clean & ConcentratorTM-5 Kit from Zymo Research.
Circular and linearized DNA templates were tested to determine which structure was
most ideal for optimal protein expression. Final concentration of circular and linearized
DNA used in the coupled transcription/translation reaction was 0.87 µg and 0.45 µg,
respectively. 20 µL TNT master mix, 0.5 µL 1mM Methionine, 4 µL DNA template
(circular plasmid) and 0.5 µL Canine Pancreatic Microsomal Membranes were added to

25

a 1.5 mL tube on ice and vortexed gently to properly mix. 20 µL TNT master mix, 0.5
µL 1 mM Methionine, 0.5 µL T7 PCR Promoter enhancer, 4 µL DNA template
(linearized plasmid) and 0.45 µL Canine Pancreatic Microsomal Membranes were added
to a 1.5 mL tube on ice and mixed as above. The samples were then placed at 30° C for a
total of 75 minutes per manufacturer’s protocol.

2.1.9 Purification of Final Protein Product
After coupled transcription/translation of the linearized and circular plasmid was
performed, the polyhistidine-tagged binding products were purified using the MagZTM
Protein Purification System from Promega. 50 µL circular and 50 µL linearized plasmid
from the coupled transcription/translation reaction were each applied to two empty 1.5
mL vials. 100 µL each MagZ Binding/Wash Buffer was then added and vials were
mixed by inverting slowly 5 times. Two 40 µL aliquots of MagZ Binding Particles were
then transferred to two empty 1.5 mL vials. Each tube was placed in a magnetic stand to
allow for separation of binding particles from the supernatant. Next, each prepared
protein solution from above was added to the vials containing the binding particles. The
mixtures were carefully pipetted to re-suspend the particles in solution. The solutions
were then incubated for 15 minutes at room temperature with gentle agitation to avoid
settling of particles at bottom of tubes.
Supernatant from each vial was then removed by placing the vials in the magnetic
stand in order to separate the beads from the mixture. 200 µL MagZ Binding/Wash
buffer was added to the particles and mixed by pipetting 5-6 times. Tubes were placed in
the magnetic stand once again to facilitate supernatant removal. This wash step was
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repeated 3 additional times. 100 µL each of Elution Buffer was added to washed beads in
both vials and mixed five times. Purified protein product was obtained by placing the
vials in the magnetic stand and removing the supernatant.

2.1.10 Protein Concentration
Purified protein products were concentrated using a Protein Concentrate (Micro)
Kit from Millipore (Temecula, Ca). 50 µL of each sample were added to two vials
containing 150 µL each of UPPA-1 Buffer and incubated on ice for 15 minutes. 150 µL
UPPA-II buffer was then added, vials were vortexed and placed in a table top
microcentrifuge at 10,000 rpm for 5 minutes. Supernatant was discarded and the pellets
were each covered with 40 µL UPC-Wash and centrifuged at 10,000 rpm for 5 minutes.
Supernatant was collect and 25 µL RNAse free water was added to each of the protein
pellets. Vials were centrifuged at 10,000 rpm for 30 seconds. 700 µL pre-chilled
Orgosol buffer and 3 µL UPC-Seed was added to each vial, vortexed and then placed at
-20° C for 30 minutes. During this period, vials were mixed intermittently for a total of
20 seconds at each time interval. Vials were then centrifuged once again at 10,000 rpm
for a total of 5 minutes. The supernatant was collected and 15 µL Precipitate Buffer I
was added to each vial. After a 2 minute incubation on ice, 3 µL Precipitate Buffer II
was added to both vials. Samples were then incubated for 5 minutes on ice and
centrifuged at 10,000 rpm for a total of 30 seconds. Clear supernatant containing the
concentrated protein product was collected from each vial.
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2.1.11 Re-Characterization of F(ab)-generating single chain antibody:
SDS-PAGE was performed to verify proper translation of the protein product. 20
µL purified protein product + 3 µL NuPAGE denaturing agent + 7.5 µL SDS-PAGE
reagent were added to a 10% polyacrylamide pre-packaged gel from NuPAGE. Proteins
were resolved by running the reaction at 150 V for a total of 30 minutes. The gel was
then stained using a Silver Staining Kit from Life Sciences in order to visualize the
protein bands.

2.1.12 Western Blot Analysis
Protein bands were transferred to a PVDF membrane by running a Western Blot
at 30 V for 60 minutes at 4 degrees Celsius. The membrane was incubated in 5% non-fat
dry milk + TBS-T for one hour and then incubated with a 1:5,000 dilution of an antimouse IgG (Fab-specific) alkaline phosphatase conjugated antibody in blocking buffer,
for a total of two hours. The membrane was then washed in TBS-T according to protocol
and bands were developed by using a SIGMAFAST™ BCIP®/NBT tablet from SigmaAldrich.

2.1.13 Statistical Analysis
Statistical analysis was performed on data obtained from the F(ab) and 7F
Competition ELISA. Using SAS 9.2 for Windows, the significance level α was set to
0.05% and a Mixed Procedure with a Diagonal Covariance Structure was performed.
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Results
The mRNA from the 7F hybridoma VH and VL coding sequence was converted to
cDNA, amplified, (Figure 3.1.1) sequenced and cloned into an expression vector with the
FMDV 2A cleavage motif placed in-frame and between the two fragments (Figure
3.1.2). The resulting expression vector was used to transfect HEK293 cells to determine
if a functional F(ab) was synthesized and secreted. Concentrated tissue culture
supernatants were purified over an affinity column and the eluate analyzed by SDS-PAGE,
which confirmed that the sequence was successfully translated, cleaved and secreted
(Figure 3.1.3). Western Blots confirmed the presence of the heavy and light chain
fragments at the predicted molecular weights, however a stronger band was observed for
the 24 kD fragment (Figure 3.1.4). Competition studies using the anti-NNK binding
fragment showed a concentration dependent inhibition of binding upon pre-incubation
with free NNK, reaching 85% at the highest concentration tested (0.48 mM) (Figure
3.1.5).
Both a cell viability assay and proliferation assay were performed to determine
the effects of NNK on transformed lung epithelial and adenocarcinoma cells. Results
were inconclusive in that both A549 and NCI-H441 cells did not respond to varying
concentrations of NNK (0.483 µM-4,830 µM) over an incubation period of 19-48 hrs.
In order to improve the binding affinity of the previously expressed F(ab), several
adjustments were made to the initial plasmid constructed by Creative Biolabs. To the
amplified VL/VH DNA sequence containing the FMDV 2A cleavage motif, a T7
Promoter, Kozak Sequence, ER cleavable signal sequence from Calreticulin, GSG
Linker, His Tag and Synthetic Poly A tag plus suitable endonuclease enzyme sites were
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added. All of these components were cloned into the expression vector pUC57 in order
to yield the final product (Figure 3.1.6). The plasmid was sequenced (Figure 3.1.7), and
then amplified for subsequent expression in a coupled transcription/translation cell-free
system. The sequence of the plasmid was re-confirmed by performing Restriction
Digests. Agarose Gel Analysis (Figure 3.1.8) confirmed that the plasmid amplified from
E-Coli TOP10 transformed bacterial cells was in fact the correct Molecular Weight (4.2
Kb), and that digestion of the plasmid with enzymes NotI and EcoRI produced an insert
of the anticipated size (1.6 Kb). SDS-PAGE analysis was inconclusive due to the
presence of several protein bands of various molecular weights (Figure 3.1.9). These
bands are most likely part of the rabbit reticulocyte lysate from the coupled
transcription/translation reaction that were co-purified with the protein. In order to
confirm that proper protein processing occurred, a Western Blot was performed using a
1:5000 dilution of an anti-mouse IgG (Fab-specific) antibody. Development of the
PVDF membrane showed that protein bands were not present.
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Figure 3.1.1: PCR amplification of the VH and VL Immunoglobulin chains of the 7F
Mab.
mRNA from the 7F hybridoma was converted to cDNA and then amplified via PCR.
Results showed two individual bands of the appropriate molecular weights. LANE 1:
PCR amplification of the VL with the κ primers; LANE 2: PCR amplification of the VH
with the VH back primers and CH1 for primers; M: molecular weight standard.
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Figure 3.1.2: The schematic map of BSA-DP-pFab-H
The BSA-DP-pFab-H eukaryotic expression vector was expressed within HEK293 cells.
The DNA of the individual Ig chains, linked by the 2A sequence, was cloned into the
vector via EcoRI/NotI.
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Figure 3.1.3: SDS-PAGE separation of purified Anti-NNK Binding Fragment
A non-denaturing SDS-PAGE revealed that expression of the F(ab) in HEK293 cells
resulted in the successful cleavage of the fusion product into two individual
Immunoglobluin chains at the anticipated molecular weights

M: Molecular Weight standard
Lane 1: Cleaved VL and VH antibody chains
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Figure 3.1.4: Western Blot
Western Blot analysis of the binding fragment expressed in HEK293 cells revealed the
presence of two protein bands at the anticipated molecular weights. An anti-mouse IgG
(Fab-specific) alk. phos. conjugated Ab was used at a 1:40,000 dilution for detection of
the individual Immunoglobulin chains.

M: Molecular Weight Standard
Lane 1: VH and VL Immunoglobulin Chains at 1:40,000 dilution of primary Ab.
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Figure 3.1.5: Competitive Inhibition of Anti-NNK Binding Fragment and 7F using
free NNK
A 10 mg/mL stock solution of NNK was diluted to initial concentrations of 26 µM, 88
µM, 292 µM, and 966 µM. A 1:4 dilution of the F(ab) was added to each concentration of
NNK to yield a final dilution of 1:8. Competition ELISA screening revealed that
approximately 84% inhibition of the construct was seen at 483 µM of NNK. At the same
concentration of NNK, 85% inhibition of the monoclonal antibody 7F was evident.
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Figure 3.1.6: Final Plasmid Construct
7F VL-CL DNA was amplified from the original 7F Fab vector using the primers
U7fvl/Dck and ligated into pUC57s via PstI/MfeI, yielding the vector designated as
pUC57s-7FVLCL. 7F VH-CH1 DNA was amplified from the 7F Fab vector using the
primers U7fvh/Dch1 and ligated into pUC57s-7FVLCL via SacII/AvrII. The identity of
the sequences were verified by DNA sequencing (Figure 3.1.7). The final vector was
designated as pUC57s-7FHL.
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Figure 3.1.7: DNA sequence of Optimized Anti-NNK Binding Fragment
Purple = T7 Promoter
Underlined = Kozak Sequence
Yellow = ER cleavable signal sequence from Calreticulin
Light Green = Variable Heavy Chain
Light Blue = Constant Heavy Chain
Dark Yellow = Furin Site
Teal = GSG Linker
Grey = 2A sequence
Pink = Variable Light Chain
Red = Constant Light Chain
Green = His Tag
Dark Grey = Synthetic Poly A tag
1 CGA
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Figure 3.1.8: Gel Analysis of DNA from Reconstructed Plasmid
An agarose gel was run to confirm the identity of the pUC57s-7FHL expression vector.
Restriction digests were performed using enzymes EcoRI and NotI. Gel analysis
revealed that the vector contained the insert and at the appropriate molecular weight.

M 1

2

3

4

5

M: Molecular Weight Marker
Lane 1: Supercoiled Plasmid
Lane 2: Linearized Plasmid
Lane 3: Empty Plasmid + Insert
Lane 4: PCR Amplified Insert
Lane 5: PCR Amplified Insert
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Figure 3.1.9: SDS-PAGE of Anti-NNK Binding Fragment
SDS-PAGE analysis was performed on the binding fragment expressed within the
coupled transcription/translation system. Results portrayed the presence of several
different protein bands at varying molecular weights, along with two bands at the
anticipated molecular weights (25 kDa).

M

1

2

75 kDa-

50 kDa37 kDa-

25 kDa-

Lane 1= Linearized Sample
Lane 2= Supercoiled Sample
M= Molecular Weight Marker
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Discussion
Immune-mediated sequestration of carcinogens and toxicants found in certain
products is an attractive means to mitigate the harmful biological effects of these
compounds. The following proposal demonstrates the feasibility of this approach when
combating the carcinogen NNK, which is abundant in smokeless tobacco. Over the past
few years, other studies have attempted to mitigate the acute toxicity effects of drugs
such as cocaine, heroin, methamphetamine, colchicine, oleander and other related
substances [26, 46, 47, 48]. This work builds upon these previous studies by attempting
to create a high affinity recombinant anti-NNK binding site derived from a monoclonal
antibody specific for NNK that was synthesized previously [49]. To increase the binding
efficiency of the antibody fragment, an FMDV 2A peptide was cloned between the
amplified VH and VL immunoglobulin chains of the monoclonal antibody. The
incorporation of this self-cleaving peptide between multiple proteins within a single
vector has been shown to significantly improve protein expression and is superior to the
IRES approach in regards to the ratios of each translated protein translated [40, 41, 50].
Amplification and cloning of the VH and VL immunoglobulin chains derived from
the 7F monoclonal antibody was successfully accomplished along with the incorporation
of the 2A peptide linker. When the construct was expressed in HEK 293 cells, the
formation of a recombinant binding fragment with a similar binding affinity to NNK as
its parent hybridoma (7F) was seen. According to competition studies, there was about a
one log loss in binding affinity.
In order to address the loss in binding affinity, the initial plasmid containing the
insert was reconstructed. We hypothesized that the original signal peptide attached
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upstream of the light chain may not have been removed upon cellular processing, thereby
interfering with proper antibody folding. This would also account for the higher
concentration of the variable light chain as seen in Figure 3.1.4. In the new construct, an
ER cleavable signal sequence from calreticulin was placed upstream of both the heavy
and light chains. A study by Felipe et al. (2004) showed that the incorporation of this
signal sequence resulted in proper subcellular localization of two processing products
[51]. Another improvement was the addition of a Gly-Ser-Gly linker between the
upstream protein and the 2A peptide. Cleavage efficiency is significantly improved by
incorporation of this linker due to increased flexibility and relaxation of unfavorable
conformations [52,53,54, 55,56]. In order to express the protein in the TNT coupled
Transcription/Translation Cell-Free system, a T7 promoter, Kozak sequence and
synthetic poly A tag were also added to the plasmid vector. The incorporation of a polyHis tag to the C-terminus of the light chain facilitated purification of the translated
protein product, which was accomplished by using the MagZ Protein Purifcation System
from Promega. Standard nickel-based resins that are usually used for purification of
polyhistidine-tagged proteins were not used in this instance due to the fact that
hemoglobin from the rabbit reticulocyte lysate binds to the resin, resulting in its coelution with the poly-histidine tagged protein.
Results from this experiment were inconclusive due to the fact that the Coupled
Transcription/Translation system failed to produce an anti-NNK binding fragment. Since
this cell-free system lacks microsomal membranes necessary for proper cellular
processing and glycosylation of proteins, the addition of canine pancreatic microsomal
membranes were necessary for protein expression. However, it has been shown that
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addition of these membranes can sometimes inhibit the transcription/translation process
by up to 50%. Since bacterial cells produced plasmid DNA at relatively small
concentrations (20 ng/ µL), it is also possible that not enough DNA was used for the
coupled transcription/translation reaction, but it is more likely that proper subcellular
processing of the protein failed to occur. Expression of the construct in HEK293 cells
would overcome this obstacle since all necessary cellular components, including
microsomal membranes, are available for proper protein production. Studies will be
conducted in the future using this cellular system in order to properly express the antiNNK binding fragment.
Exposure of transformed lung epithelial and adenocarcinoma cells (NCI-H441
and A549) to varying concentrations of NNK produced inconclusive results. Cells did not
respond to NNK, even when incubated with very high concentrations (4,830 µM). This
finding contradicts several others showing NNK to be a strong tumor-promoter, even in
minute quantities [57, 58, 6, 59]. One reason for this could be the aberrant mutation of
α7 nicotinic acetylcholine receptors within the cells due to high cell passage number,
which would render them unresponsive to NNK. As mentioned previously, NNK ligation
with these receptors is essential to activation of primary transcription factors necessary
for the promotion of cellular proliferation/differentiation. Another possible reason for
this finding could be inactivation of the NNK itself. NNK is sensitive to light/ UV
exposure and if pH conditions are not optimal, can break down rather easily. Future
studies need to be conducted in order to test the validity/reliability of these results.
The current study provided proof of principal for the ability of a recombinant
binding fragment derived from an anti-NNK monoclonal antibody to successfully
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sequester the carcinogen. This work paves the way for potential tobacco harm reduction
immunotherapeutics that may one day be marketed in order to provide a less hazardous
product for long-term tobacco users.
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